Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche

MYTD Revenues: $18.6 billion (+15%)

MYTD Earnings: $4.1 billion (+29%)

Comments: Pharmaceutical sales increased 18% to $9.3 billion for the half-year. Growth was driven by key oncology drugs (MabThera/Rituxan, Herceptin, Avastin, Xeloda and Tarceva), up 22%, as well as metabolism, (Bonviva/Boniva up 127% to $304 million) transplantation and virology drugs, including increased Tamiflu sales for pandemic stockpiling. Lucentis, Genentech’s recently launched medicine for age-related blindness, was also a contributor to growth. Herceptin, Avastin and Xeloda approved for additional cancer indications in the EU and Japan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters